A recent study reveals that Lepidium draba L. (L. draba) extract may shield the liver and kidneys from damage caused by cyclophosphamide (CP), a common chemotherapy drug. Published by researchers including Yu-Lai You and Sheng Zheng in Asian Pacific Journal of Tropical Biomedicine, the study demonstrates how the extract reduces oxidative stress, inflammation, and cell death in rats. These findings could lead to new therapies for mitigating chemotherapy-induced toxicity.
The research team divided 36 rats into six groups, including a control group, a CP-treated group, and groups receiving varying doses of L. draba extract alongside CP. The extract significantly lowered markers of liver and kidney damage, such as nitric oxide and pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β), while boosting antioxidant enzymes like superoxide dismutase.
Key findings include:
- Reduced apoptosis: The extract downregulated pro-apoptotic genes (Bax and caspase-3) and preserved tissue structure in the liver and kidneys.
- Anti-inflammatory effects: Levels of protective cytokines (TGF-β) increased, countering CP-induced inflammation.
- Histopathological improvements: The extract mitigated damage to renal tubules and hepatocytes, as seen in microscopic analyses.
“L. draba extract not only combats oxidative stress but also addresses the inflammatory and apoptotic pathways triggered by cyclophosphamide,” noted the authors.
The study highlights L. draba extract’s potential as a complementary therapy to protect organs during chemotherapy. Future research will explore its applicability in human trials, offering hope for reducing the adverse effects of cancer treatments.
Add comment